-
公开(公告)号：US20230010772A1
公开(公告)日：2023-01-12
申请号：US17782632
申请日：2020-12-04
Applicant: UNIVERSITY HEALTH NETWORK
Inventor： Mark R. Bray , Jacqueline M. Mason , Graham Fletcher
IPC: A61K31/5377 , A61K31/635 , A61K31/706 , A61P35/00 , A61K9/00
Abstract: The invention is related to a method of treating a subject with acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia, non-Hodgkin’s lymphoma, Burkitt lymphoma, or diffuse large B-cell lymphoma, or myelodysplastic syndrome by administration of Compound (I): (I), or a pharmaceutically acceptable salt thereof.
-
公开(公告)号：US20220089725A1
公开(公告)日：2022-03-24
申请号：US17430311
申请日：2020-02-14
Applicant: UNIVERSITY HEALTH NETWORK
Inventor： Richard Brokx , Jacqueline M. Mason , Mark R. Bray
Abstract: The invention provides novel anti-FCMR antibodies, pharmaceutical compositions comprising such antibodies, and therapeutic methods of using such antibodies and pharmaceutical compositions for the treatment of diseases such as cancer or autoimmune disease.
-
公开(公告)号：US20190225617A1
公开(公告)日：2019-07-25
申请号：US16258753
申请日：2019-01-28
Applicant: University Health Network
Inventor： Radoslaw Laufer , Grace Ng , Richard Brokx , Heinz W. Pauls , Sze-Wan Li , Jacqueline M. Mason , Mark R. Bray
IPC: C07D487/04 , A61P35/00 , A61P29/00 , A61K31/519 , A61K45/06 , A61P37/06
Abstract: The invention is a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. Values for the variables are provided herein. Also included is a pharmaceutical composition comprising the compound represented by Structural Formula (I) and a pharmaceutically acceptable carrier or diluent and methods of treating a subject with cancer with the compound of Structural Formula (I).
-
公开(公告)号：US09642856B2
公开(公告)日：2017-05-09
申请号：US15029269
申请日：2014-10-03
Applicant: University Health Network
Inventor： David W. Hedley , Ines Lohse , Jacqueline M. Mason , Mark R. Bray
IPC: A61K31/5377 , A61K31/416 , A61P35/00 , C07D413/14 , A61K45/06 , A61K31/7068 , A61K33/24
CPC classification number: A61K31/5377 , A61K31/7068 , A61K33/24 , A61K45/06 , C07D403/08 , C07D413/14 , A61K2300/00
Abstract: The invention is related to a method of treating a subject with pancreatic cancer with administration of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof.
-
公开(公告)号：US20150182504A1
公开(公告)日：2015-07-02
申请号：US14592968
申请日：2015-01-09
Applicant: UNIVERSITY HEALTH NETWORK
Inventor： Guohua Pan , Jacqueline M. Mason , Xin Wei , Miklos Feher
IPC: A61K31/416 , A61K31/4439 , A61K31/5377 , A61K31/496
CPC classification number: A61K31/416 , A61K31/4439 , A61K31/495 , A61K31/496 , A61K31/497 , A61K31/5377
Abstract: Provided herein are methods and compositions for treating a patient with cancer wherein the cancer is characterized by a PTEN gene mutation and/or a PI3K gene mutation. In particular embodiments, the methods comprise administering to the patient a composition comprising a therapeutically effective amount of a PLK4 antagonist.
Abstract translation: 本文提供了用于治疗癌症患者的方法和组合物，其中癌症的特征在于PTEN基因突变和/或PI3K基因突变。 在具体实施方案中，所述方法包括向患者施用包含治疗有效量的PLK4拮抗剂的组合物。
-
Patent Agency Ranking
公开(公告)号：US12286476B2
公开(公告)日：2025-04-29
申请号：US17430311
申请日：2020-02-14
Applicant: UNIVERSITY HEALTH NETWORK
Inventor： Richard Brokx , Jacqueline M. Mason , Mark R. Bray
Abstract: The invention provides novel anti-FCMR antibodies, pharmaceutical compositions comprising such antibodies, and therapeutic methods of using such antibodies and pharmaceutical compositions for the treatment of diseases such as cancer or autoimmune disease.
-
公开(公告)号：US20230144869A1
公开(公告)日：2023-05-11
申请号：US17917995
申请日：2021-04-12
Applicant: UNIVERSITY HEALTH NETWORK
Inventor： Mark R. Bray , Jacqueline M. Mason , Xin Wei , Gordon Duncan
IPC: A61K31/496 , A61P37/06
CPC classification number: A61K31/496 , A61P37/06
Abstract: Disclosed herein is a method of treating a subject with aberrant cytokine release from a disease or condition or at risk of developing aberrant cytokine release from a disease or condition. The method comprises administering to the subject an effective amount of a compound represented by structural formula (I): (I) or a pharmaceutically acceptable salt thereof. The variables in structural formula (I) are as described herein.
-
公开(公告)号：US20220153834A1
公开(公告)日：2022-05-19
申请号：US17434368
申请日：2020-03-11
Applicant: UNIVERSITY HEALTH NETWORK
Inventor： Richard Brokx , Jacqueline M. Mason , Mark R. Bray
Abstract: The invention provides novel anti-TSG-6 antibodies, pharmaceutical compositions comprising such antibodies, and therapeutic methods of using such antibodies and pharmaceutical compositions for the treatment of diseases such as cancer or autoimmune disease.
-
公开(公告)号：US20220089723A1
公开(公告)日：2022-03-24
申请号：US17421705
申请日：2020-01-16
Applicant: UNIVERSITY HEALTH NETWORK
Inventor： Richard Brokx , Jacqueline M. Mason , Mark R. Bray
IPC: C07K16/28
Abstract: The invention provides novel anti-LILRB3 antibodies, pharmaceutical compositions comprising such antibodies, and therapeutic methods of using such antibodies and pharmaceutical compositions for the treatment of diseases such as cancer, autoimmune disease, or allergic inflammation This invention can also be used to modulate osteoclast differentiation.
-
公开(公告)号：US20210261554A1
公开(公告)日：2021-08-26
申请号：US17134270
申请日：2020-12-26
Applicant: UNIVERSITY HEALTH NETWORK
Inventor： Radoslaw Laufer , Grace Ng , Richard Brokx , Heinz W. Pauls , Sze-Wan Li , Jacqueline M. Mason , Mark R. Bray
IPC: C07D487/04 , A61K31/519 , A61K45/06 , A61P37/06 , A61P29/00 , A61P35/00
Abstract: The invention is a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. Values for the variables are provided herein. Also included is a pharmaceutical composition comprising the compound represented by Structural Formula (I) and a pharmaceutically acceptable carrier or diluent and methods of treating a subject with cancer with the compound of Structural Formula (I).
-
-
-
-
-
-
-
-
-
Search Results
22
records
(took 0.019 seconds)
